Stock Analysis on Net
Stock Analysis on Net

Baxter International Inc. (NYSE:BAX)

This company has been moved to the archive! The financial data has not been updated since August 4, 2016.

Common Stock Valuation Ratios (Price Multiples) 
Quarterly Data

Microsoft Excel

Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).

Historical Valuation Ratios (Summary)

Baxter International Inc., historical price multiples (quarterly data)

Microsoft Excel
Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011
Price to earnings (P/E) 5.45 6.35 22.32 12.01 10.47 15.82 14.92 20.41 21.18 19.59 18.71 16.43 17.87 16.31 15.59 15.23 13.86 13.61 14.26 — — —
Price to operating profit (P/OP) 49.72 45.67 48.11 19.27 14.69 17.63 13.76 16.16 16.78 15.05 14.11 12.84 13.70 13.14 12.85 12.17 11.17 10.54 10.76 — — —
Price to sales (P/S) 2.60 2.50 2.17 1.74 1.69 2.46 2.23 2.30 2.55 2.52 2.47 2.45 2.76 2.62 2.56 2.49 2.26 2.18 2.28 — — —
Price to book value (P/BV) 3.07 2.76 2.44 2.63 2.86 5.17 4.59 4.54 4.76 4.55 4.45 4.62 5.44 5.37 5.23 4.90 4.84 4.54 4.82 4.43 4.54 4.92

Based on: 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Baxter International Inc. P/E ratio decreased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Baxter International Inc. P/OP ratio decreased from Q4 2015 to Q1 2016 but then increased from Q1 2016 to Q2 2016 exceeding Q4 2015 level.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Baxter International Inc. P/S ratio increased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Baxter International Inc. P/BV ratio increased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016.

Price to Earnings (P/E)

Baxter International Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011
No. shares of common stock outstanding1 543,887,683 552,262,740 547,871,849 547,017,700 545,538,967 544,254,211 542,581,466 541,978,180 541,673,382 542,599,898 543,187,695 542,697,603 542,786,732 541,952,040 545,928,648 549,377,920 547,231,164 550,595,361 560,346,203 563,866,130 568,256,444 570,377,620
Selected Financial Data (US$)
Net income attributable to Baxter (in millions) 1,212 3,380 205 1 332 430 953 468 520 556 326 544 590 552 494 583 661 588 463 576 615 570
Earnings per share (EPS)2 8.82 7.09 1.77 3.14 4.00 4.36 4.60 3.45 3.59 3.72 3.70 4.02 4.09 4.23 4.26 4.18 4.18 4.07 3.97 0.00 0.00 0.00
Share price1, 3 48.08 45.07 39.43 37.66 41.88 68.91 68.67 70.41 76.09 72.79 69.29 65.99 73.04 68.91 66.42 63.61 57.95 55.40 56.59 54.57 55.92 58.06
Valuation Ratio
P/E ratio4 5.45 6.35 22.32 12.01 10.47 15.82 14.92 20.41 21.18 19.59 18.71 16.43 17.87 16.31 15.59 15.23 13.86 13.61 14.26 — — —
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories — — — — — — — — — — — — — — — — — — — — — —
Cigna Group — — — — — — — — — — — — — — — — — — — — — —
CVS Health Corp. — — — — — — — — — — — — — — — — — — — — — —
Elevance Health Inc. — — — — — — — — — — — — — — — — — — — — — —
Humana Inc. — — — — — — — — — — — — — — — — — — — — — —
Intuitive Surgical Inc. — — — — — — — — — — — — — — — — — — — — — —
Medtronic PLC — — — — — — — — — — — — — — — — — — — — — —
UnitedHealth Group Inc. — — — — — — — — — — — — — — — — — — — — — —

Based on: 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2016 Calculation
EPS = (Net income attributable to BaxterQ2 2016 + Net income attributable to BaxterQ1 2016 + Net income attributable to BaxterQ4 2015 + Net income attributable to BaxterQ3 2015) ÷ No. shares of common stock outstanding
= (1,212,000,000 + 3,380,000,000 + 205,000,000 + 1,000,000) ÷ 543,887,683 = 8.82

3 Closing price as at the filing date of Baxter International Inc. Quarterly or Annual Report.

4 Q2 2016 Calculation
P/E ratio = Share price ÷ EPS
= 48.08 ÷ 8.82 = 5.45

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Baxter International Inc. P/E ratio decreased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016.

Price to Operating Profit (P/OP)

Baxter International Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011
No. shares of common stock outstanding1 543,887,683 552,262,740 547,871,849 547,017,700 545,538,967 544,254,211 542,581,466 541,978,180 541,673,382 542,599,898 543,187,695 542,697,603 542,786,732 541,952,040 545,928,648 549,377,920 547,231,164 550,595,361 560,346,203 563,866,130 568,256,444 570,377,620
Selected Financial Data (US$)
Operating income (in millions) 68 188 178 92 87 92 798 578 659 672 453 672 828 715 574 777 777 693 625 745 831 745
Operating profit per share2 0.97 0.99 0.82 1.95 2.85 3.91 4.99 4.36 4.53 4.84 4.91 5.14 5.33 5.25 5.17 5.23 5.19 5.26 5.26 0.00 0.00 0.00
Share price1, 3 48.08 45.07 39.43 37.66 41.88 68.91 68.67 70.41 76.09 72.79 69.29 65.99 73.04 68.91 66.42 63.61 57.95 55.40 56.59 54.57 55.92 58.06
Valuation Ratio
P/OP ratio4 49.72 45.67 48.11 19.27 14.69 17.63 13.76 16.16 16.78 15.05 14.11 12.84 13.70 13.14 12.85 12.17 11.17 10.54 10.76 — — —
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories — — — — — — — — — — — — — — — — — — — — — —
Cigna Group — — — — — — — — — — — — — — — — — — — — — —
CVS Health Corp. — — — — — — — — — — — — — — — — — — — — — —
Elevance Health Inc. — — — — — — — — — — — — — — — — — — — — — —
Humana Inc. — — — — — — — — — — — — — — — — — — — — — —
Intuitive Surgical Inc. — — — — — — — — — — — — — — — — — — — — — —
Medtronic PLC — — — — — — — — — — — — — — — — — — — — — —
UnitedHealth Group Inc. — — — — — — — — — — — — — — — — — — — — — —

Based on: 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2016 Calculation
Operating profit per share = (Operating incomeQ2 2016 + Operating incomeQ1 2016 + Operating incomeQ4 2015 + Operating incomeQ3 2015) ÷ No. shares of common stock outstanding
= (68,000,000 + 188,000,000 + 178,000,000 + 92,000,000) ÷ 543,887,683 = 0.97

3 Closing price as at the filing date of Baxter International Inc. Quarterly or Annual Report.

4 Q2 2016 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 48.08 ÷ 0.97 = 49.72

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Baxter International Inc. P/OP ratio decreased from Q4 2015 to Q1 2016 but then increased from Q1 2016 to Q2 2016 exceeding Q4 2015 level.

Price to Sales (P/S)

Baxter International Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011
No. shares of common stock outstanding1 543,887,683 552,262,740 547,871,849 547,017,700 545,538,967 544,254,211 542,581,466 541,978,180 541,673,382 542,599,898 543,187,695 542,697,603 542,786,732 541,952,040 545,928,648 549,377,920 547,231,164 550,595,361 560,346,203 563,866,130 568,256,444 570,377,620
Selected Financial Data (US$)
Net sales (in millions) 2,585 2,375 2,603 2,487 2,475 2,403 4,472 4,197 4,154 3,848 4,368 3,774 3,669 3,448 3,753 3,477 3,572 3,388 3,594 3,479 3,536 3,284
Sales per share2 18.48 18.00 18.19 21.64 24.83 27.98 30.73 30.57 29.80 28.86 28.09 26.98 26.43 26.29 25.99 25.54 25.64 25.42 24.79 0.00 0.00 0.00
Share price1, 3 48.08 45.07 39.43 37.66 41.88 68.91 68.67 70.41 76.09 72.79 69.29 65.99 73.04 68.91 66.42 63.61 57.95 55.40 56.59 54.57 55.92 58.06
Valuation Ratio
P/S ratio4 2.60 2.50 2.17 1.74 1.69 2.46 2.23 2.30 2.55 2.52 2.47 2.45 2.76 2.62 2.56 2.49 2.26 2.18 2.28 — — —
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories — — — — — — — — — — — — — — — — — — — — — —
Cigna Group — — — — — — — — — — — — — — — — — — — — — —
CVS Health Corp. — — — — — — — — — — — — — — — — — — — — — —
Elevance Health Inc. — — — — — — — — — — — — — — — — — — — — — —
Humana Inc. — — — — — — — — — — — — — — — — — — — — — —
Intuitive Surgical Inc. — — — — — — — — — — — — — — — — — — — — — —
Medtronic PLC — — — — — — — — — — — — — — — — — — — — — —
UnitedHealth Group Inc. — — — — — — — — — — — — — — — — — — — — — —

Based on: 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2016 Calculation
Sales per share = (Net salesQ2 2016 + Net salesQ1 2016 + Net salesQ4 2015 + Net salesQ3 2015) ÷ No. shares of common stock outstanding
= (2,585,000,000 + 2,375,000,000 + 2,603,000,000 + 2,487,000,000) ÷ 543,887,683 = 18.48

3 Closing price as at the filing date of Baxter International Inc. Quarterly or Annual Report.

4 Q2 2016 Calculation
P/S ratio = Share price ÷ Sales per share
= 48.08 ÷ 18.48 = 2.60

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Baxter International Inc. P/S ratio increased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016.

Price to Book Value (P/BV)

Baxter International Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011
No. shares of common stock outstanding1 543,887,683 552,262,740 547,871,849 547,017,700 545,538,967 544,254,211 542,581,466 541,978,180 541,673,382 542,599,898 543,187,695 542,697,603 542,786,732 541,952,040 545,928,648 549,377,920 547,231,164 550,595,361 560,346,203 563,866,130 568,256,444 570,377,620
Selected Financial Data (US$)
Total Baxter shareholders’ equity (in millions) 8,509 9,019 8,846 7,824 7,988 7,258 8,120 8,404 8,662 8,671 8,463 7,749 7,282 6,961 6,938 7,129 6,551 6,725 6,585 6,952 6,997 6,734
Book value per share (BVPS)2 15.64 16.33 16.15 14.30 14.64 13.34 14.97 15.51 15.99 15.98 15.58 14.28 13.42 12.84 12.71 12.98 11.97 12.21 11.75 12.33 12.31 11.81
Share price1, 3 48.08 45.07 39.43 37.66 41.88 68.91 68.67 70.41 76.09 72.79 69.29 65.99 73.04 68.91 66.42 63.61 57.95 55.40 56.59 54.57 55.92 58.06
Valuation Ratio
P/BV ratio4 3.07 2.76 2.44 2.63 2.86 5.17 4.59 4.54 4.76 4.55 4.45 4.62 5.44 5.37 5.23 4.90 4.84 4.54 4.82 4.43 4.54 4.92
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories — — — — — — — — — — — — — — — — — — — — — —
Cigna Group — — — — — — — — — — — — — — — — — — — — — —
CVS Health Corp. — — — — — — — — — — — — — — — — — — — — — —
Elevance Health Inc. — — — — — — — — — — — — — — — — — — — — — —
Humana Inc. — — — — — — — — — — — — — — — — — — — — — —
Intuitive Surgical Inc. — — — — — — — — — — — — — — — — — — — — — —
Medtronic PLC — — — — — — — — — — — — — — — — — — — — — —
UnitedHealth Group Inc. — — — — — — — — — — — — — — — — — — — — — —

Based on: 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2016 Calculation
BVPS = Total Baxter shareholders’ equity ÷ No. shares of common stock outstanding
= 8,509,000,000 ÷ 543,887,683 = 15.64

3 Closing price as at the filing date of Baxter International Inc. Quarterly or Annual Report.

4 Q2 2016 Calculation
P/BV ratio = Share price ÷ BVPS
= 48.08 ÷ 15.64 = 3.07

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Baxter International Inc. P/BV ratio increased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016.